NeuroMetrix (NASDAQ:NURO) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note issued on Thursday. The brokerage set a “sell” rating on the medical device company’s stock.

NeuroMetrix Price Performance

NeuroMetrix stock opened at $4.27 on Thursday. The company has a market cap of $8.71 million, a price-to-earnings ratio of -0.93 and a beta of 2.29. The firm has a 50-day moving average of $4.08 and a 200-day moving average of $3.84. NeuroMetrix has a one year low of $2.66 and a one year high of $4.73.

NeuroMetrix (NASDAQ:NURO) last announced its quarterly earnings data on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share (EPS) for the quarter. The company had revenue of $0.59 million for the quarter. NeuroMetrix had a negative return on equity of 42.56% and a negative net margin of 203.71%. During the same quarter in the prior year, the company posted ($1.66) EPS.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.